Latest News

March 23, 2023
March 23, 2023
Categories

The Spring 2023 advocacy blog Considering Clinical Trials is now available

Do you like it?
Read more
March 21, 2023
March 21, 2023
Categories

In this video interview, Dr. Neha Vapiwala discusses the INDICATE (EA8191) trial and changing the trajectory of prostate cancer through radiation and imaging techniques

Do you like it?
Read more
March 8, 2023
March 8, 2023
Categories

The ComboMATCH patient registration trial and three treatment trials are now open

Do you like it?
Read more
February 27, 2023
February 27, 2023
Categories

The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy

Do you like it?
Read more
February 23, 2023
February 23, 2023
Categories

A focus on the DREAMseq trial reveals data-driven clinical insights into the selection of first-line treatment options for patients with BRAF-mutated metastatic melanoma

Do you like it?
Read more
Load more

Tweets

ECOG-ACRIN Cancer Research Group Follow

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

eaonc
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
21h

#ClinicalTrial EA2176, led by @CathyEngMD of @VUMC_Cancer is testing if adding #immunotherapy to chemotherapy could help reduce symptoms and stop tumor growth in patients with #AnalCancer. Learn more: https://bit.ly/ea2176-study #ancsm

Reply on Twitter 1640761171753009174 Retweet on Twitter 1640761171753009174 1 Like on Twitter 1640761171753009174 2 Twitter 1640761171753009174
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
22h

#Clinicaltrial EA8184, led by Dr. Nagi Kumar of @MoffittNews will evaluate if #greentea catechins can help prevent the progression of #prostatecancer in men on active surveillance. Learn more here: https://bit.ly/ea8184trial #pcsm cc: @jpowsang

Reply on Twitter 1640746133302530049 Retweet on Twitter 1640746133302530049 Like on Twitter 1640746133302530049 2 Twitter 1640746133302530049
eaonc ECOG-ACRIN Cancer Research Group @eaonc ·
23h

EA9152 is a phase Ib/II study of venetoclax in combination with vincristine sulfate in patients with relapsed or refractory T-cell or B-cell #ALL. For more information: https://bit.ly/EA9152 #leukemia #leusm cc: @SelinaLugerMD

Reply on Twitter 1640731109586608129 Retweet on Twitter 1640731109586608129 Like on Twitter 1640731109586608129 Twitter 1640731109586608129
Load More

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Home
52

Active Clinical Trials

Home
1300

Participating Institutions

Home
67

International Sites

Home
15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group